BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33681387)

  • 1. Low Distribution of TIM-3
    Zhuang C; Ni B; Zhang ZZ; Zhao WY; Tu L; Ma XL; Yang LX; Cao H; Wang M
    J Immunol Res; 2021; 2021():6647292. PubMed ID: 33681387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
    Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
    Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
    Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
    Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
    Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
    J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
    Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
    Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.
    Nakano M; Ito M; Tanaka R; Yamaguchi K; Ariyama H; Mitsugi K; Yoshihiro T; Ohmura H; Tsuruta N; Hanamura F; Sagara K; Okumura Y; Nio K; Tsuchihashi K; Arita S; Kusaba H; Akashi K; Baba E
    Cancer Sci; 2018 Sep; 109(9):2986-2992. PubMed ID: 30187676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
    Wei ZW; Wu J; Huang WB; Li J; Lu XF; Yuan YJ; Xiong WJ; Zhang XH; Wang W; He YL; Zhang CH
    EBioMedicine; 2020 Jul; 57():102850. PubMed ID: 32574962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
    Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
    Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIM-3/Galectin-9 and CD160 expression in salivary adenoid cystic carcinoma.
    Li M; Wan ZX; Tang YY; Liang XH; Tang YL
    Oral Dis; 2024 May; 30(4):2262-2274. PubMed ID: 37455567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.